Watershed Therapeutics Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • Crowdfunding

  • Latest Deal Amount
  • $870K

  • Investors
  • 15

Watershed Therapeutics General Information

Description

Developer of a targeted drug delivery technology designed to deliver long-term therapies directly to the bladder with minimal procedures and improved patient comfort. The company offers localized delivery systems for the prevention of bladder cancer, overactive bladder, and recurrent urinary tract conditions, enabling urologists and patients to achieve sustained treatment effectiveness with reduced procedural burden.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 454 North 34th Street
  • Seattle, WA 98103
  • United States
+1 (314)
Primary Industry
Drug Delivery
Other Industries
Pharmaceuticals
Vertical(s)
Corporate Office
  • 454 North 34th Street
  • Seattle, WA 98103
  • United States
+1 (314)

Watershed Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Watershed Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Equity Crowdfunding 01-May-2026 $870K Completed Clinical Trials - Phase 1
7. Later Stage VC 04-Apr-2026 Completed Clinical Trials - Phase 1
6. Seed Round 01-Nov-2025 Completed Clinical Trials - Phase 1
5. Grant 01-Jan-2025 Completed Clinical Trials - Phase 1
4. Seed Round 07-Apr-2024 Completed Pre-Clinical Trials
3. Accelerator/Incubator 10-Jan-2024 Completed Pre-Clinical Trials
2. Accelerator/Incubator 01-Sep-2022 $3.67M Completed Pre-Clinical Trials
1. Seed Round 15-Aug-2022 $3.67M $3.67M Completed Pre-Clinical Trials
To view Watershed Therapeutics’s complete valuation and funding history, request access »

Watershed Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series CF
Seed-4
Seed-3
Seed-2
Seed-1 212,689 $0.000100 $0.04 $0.45 $0.45 1x $0.45 1.12%
Bridge 2,542,684 $0.000100 $0.08 $1.05 $1.05 1x $1.05 13.4%
To view Watershed Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Watershed Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a targeted drug delivery technology designed to deliver long-term therapies directly to the bladder with mi
Drug Delivery
Seattle, WA
7 As of 2026

Raanana, Israel

Saint-Laurent, Canada
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Watershed Therapeutics Competitors (7)

One of Watershed Therapeutics’s 7 competitors is Trigone Pharma, a Corporation company based in Raanana, Israel.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Trigone Pharma Corporation Raanana, Israel
EnGene Therapeutics Formerly VC-backed Saint-Laurent, Canada
Urogen Pharma Formerly VC-backed Princeton, NJ
Relmada Therapeutics Formerly VC-backed Coral Gables, FL
ImmunityBio Formerly VC-backed San Diego, CA
You’re viewing 5 of 7 competitors. Get the full list »

Watershed Therapeutics Patents

Watershed Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260315764-A1 System and method for sustained release of agents in the bladder Pending 09-Apr-2025
WO-2026217851-A1 System and method for sustained release of agents in the bladder Pending 09-Apr-2025
AU-2024311211-A1 System and method for sustained release of agents in the bladder Pending 30-Jun-2023
EP-4734966-A2 System and method for sustained release of agents in the bladder Pending 30-Jun-2023
WO-2025007091-A2 System and method for sustained release of agents in the bladder Inactive 30-Jun-2023 A61P31/00
To view Watershed Therapeutics’s complete patent history, request access »

Watershed Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Watershed Therapeutics Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds
Device of Tomorrow Capital Venture Capital Minority
Highcroft Capital Venture Capital Minority
U.S. Department of Health and Human Services Government
Charleston Angel Partners Angel Group Minority
Serial Stage Venture Partners Venture Capital Minority
You’re viewing 5 of 15 investors. Get the full list »

Watershed Therapeutics FAQs

  • When was Watershed Therapeutics founded?

    Watershed Therapeutics was founded in 2019.

  • Where is Watershed Therapeutics headquartered?

    Watershed Therapeutics is headquartered in Seattle, WA.

  • What is the size of Watershed Therapeutics?

    Watershed Therapeutics has 7 total employees.

  • What industry is Watershed Therapeutics in?

    Watershed Therapeutics’s primary industry is Drug Delivery.

  • Is Watershed Therapeutics a private or public company?

    Watershed Therapeutics is a Private company.

  • What is the current valuation of Watershed Therapeutics?

    The current valuation of Watershed Therapeutics is .

  • What is Watershed Therapeutics’s current revenue?

    The current revenue for Watershed Therapeutics is .

  • How much funding has Watershed Therapeutics raised over time?

    Watershed Therapeutics has raised $10.1M.

  • Who are Watershed Therapeutics’s investors?

    Device of Tomorrow Capital, Highcroft Capital, U.S. Department of Health and Human Services, Charleston Angel Partners, and Serial Stage Venture Partners are 5 of 15 investors who have invested in Watershed Therapeutics.

  • Who are Watershed Therapeutics’s competitors?

    Trigone Pharma, EnGene Therapeutics, Urogen Pharma, Relmada Therapeutics, and ImmunityBio are some of the 7 competitors of Watershed Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process